

Amendments to the Claims:

This listing of claims will replace all prior versions listings of claims in the application.

Listing of Claims:

1 -2 (Cancelled)

3. (Currently Amended) ~~The anti-HIV A peptide according to claim 1, wherein the peptide is selected from the group consisting of:~~

SEQ. ID. NO.: 1 Phe Asn Leu Thr His Phe Leu,

SEQ. ID. NO.: 2 Glu Gly Trp His Ala His Thr,

SEQ. ID. NO.: 3 Lys Leu Asn Trp Met Phe Thr,

SEQ. ID. NO.: 4 Ser Thr Asn Trp Met Phe Thr,

SEQ. ID. NO.: 5 Ala Met Pro Leu Pro Tyr Thr Phe,

SEQ. ID. NO.: 6 Asp Ser His Thr Pro Gln Arg,

SEQ. ID. NO.: 7 Val Ser Phe Thr Pro Ser Phe

SEQ. ID. NO.: 8 His Ala Ala Leu Ser Met Asn Thr His Ala Leu Met,

SEQ. ID. NO.: 9 Ala Trp His Glu Ser Arg Ala, and

SEQ. ID. NO.: 10 Phe Lys Thr Ala Tyr Pro Thr, and

SEQ. ID. NO.: 11 ~~Ser His Ala Leu Pro Leu Thr Trp Ser Thr Ala Ala.~~

4. (Currently Amended) A peptide comprising at least two anti-HIV peptides according to claim 3.

5. (Currently Amended) The peptide according to claim 4, wherein the anti-HIV peptides are identical.

6. (Currently Amended) The peptide according to claim 5, wherein the two anti-HIV peptides are linked by means of a spacer arm ~~consisting of~~ comprising the amino acid sequence Gly Pro Gly.

7. (Withdrawn) A conjugate comprising at least two peptides according to claims 3, 4, 5 or 6 ~~one peptide according to claim 3~~ bound to a carrier molecule, wherein the immunogenicity of the peptide is induced or enhanced.

8. (Withdrawn) The conjugate according to claim 7, wherein the carrier molecule comprises at least one helper T epitope of the HIV virus.
9. (Withdrawn) The conjugate according to claim 8, wherein the carrier molecule comprises HIV p24E or T1 epitopes.
10. (Withdrawn) The conjugate according to claim 9, comprising a first peptide selected from the sequences SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:4 linked to an identical second peptide by a Gly Pro Gly spacer to form a linked peptide, said linked peptide being bound on the N-terminal side by a spacer to the p24E epitope and the C-terminal side by a spacer to the T1 epitope.
11. (Withdrawn) The conjugate according to claim 10, wherein the spacers bound to the p24E and T1 epitopes are identical and ~~consist of~~ comprise the linkage Gly Pro Gly and wherein the linked peptide comprises any one of SEQ. ID. NOS.: ~~12 to 14~~; SEQ ID NO:12, SEQ ID NO:13 and SEQ ID NO:14.

SEQ. ID. NO.: 12 — ~~Gly Pro Lys Glu Pro Phe Arg Asp Tyr Val Asp Arg Phe Tyr Lys Gly Pro Gly Lys
Leu Asn Trp Met Phe Thr Gly Pro Gly Lys Leu Asn Trp Met Phe Thr Gly Pro Gly
Lys Gln Ile Ile Asn Met Trp Gln Glu Val Glu Lys Ala Met Tyr Ala;~~

SEQ. ID. NO.: 13 — ~~Gly Pro Lys Glu Pro Phe Arg Asp Tyr Val Asp Arg Phe Tyr Lys Gly Pro Gly Ser
Thr Asn Trp Met Phe Thr Gly Pro Gly Ser Thr Asn Trp Met Phe Thr Gly Pro Gly
Lys Gln Ile Ile Asn Met Trp Gln Glu Val Glu Lys Ala Met Tyr Ala; or~~

SEQ. ID. NO.: 14 — ~~Gly Pro Lys Glu Pro Phe Arg Asp Tyr Val Asp Arg Phe Tyr Lys Gly Pro Gly Phe
Asn Leu Thr His Phe Leu Gly Pro Gly Phe Asn Leu Thr His Phe Leu Gly Pro Gly
Lys Gln Ile Ile Asn Met Trp Gln Glu Val Glu Lys Ala Met Tyr Ala.~~

12-28 (Cancelled)

29. (New) The conjugate according to claim 7 wherein the immunogenicity of at least one of the peptides is induced or enhanced.